This site is intended for healthcare professionals
Drug information

Deximune 100 mg soft capsules

POM
Read time: 35 mins
Last updated: 29 Sep 2020
Published: 30 Jul 2021
...
 

4.1 Therapeutic indications

Transplantation Indications

Solid Organ Transplantation

Prevention of graft rejection following solid organ transplantation.

Treatment of transplant rejection in patients previously receiving other immunosuppressive agents.

Bone Marrow Transplantation

Prevention of graft rejection following allogeneic bone marrow and stem cell transplantation.

Prevention or treatment of graft-versus-host disease (GVHD).

Non-Transplantation Indications

Endogenous uveitis

Treatment of sight-threatening intermediate or posterior uveitis of non-infectious aetiology in patients in whom conventional therapy has failed or caused unacceptable side effects.

Treatment of Behçet uveitis with repeated inflammatory attacks involving the retina in patients without neurological manifestations.

Psoriasis

Deximune Capsules are indicated in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate.

Atopic Dermatitis

Deximune Capsules are indicated in patients with severe atopic dermatitis when systemic therapy is required.

Rheumatoid Arthritis

Deximune Capsules are indicated for the treatment of severe, active rheumatoid arthritis.

Nephrotic Syndrome

Steroid-dependent and steroid-resistant nephrotic syndrome due to primary glomerular diseases such as minimal change nephropathy, focal segmental glomerulosclerosis or membranous glomerulonephritis.

Deximune Capsules can be used to induce remissions and for maintenance remissions. It can also be used to maintain steroid-induced remission, allowing withdrawal of steroids.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Click here to register now

Drug section
Learning Zone Homepage

Atopic Dermatitis Learning Zone

Welcome to the Atopic Dermatitis Learning Zone, an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Read more
335 mins
Learning Zone Homepage

Transplantation Learning Zone

Welcome to the Transplantation Learning Zone, an online resource intended to educate healthcare professionals in best practice for the transplantation of various organs.

Read more
730 mins
Learning Zone Homepage

Optimising anti-TNF treatment using biosimilars

Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.

Read more
85 mins

Clinical trial
Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants

The Phase 2 primary objective is to evaluate achievement of persistent mixed chimerism and withdrawal of at least one immunosuppression drug for a minimum of 6 months with no episodes of biopsy-proven acute rejection or transplant kidney loss induced by cellular immunotherapy with MDR-102 in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants.

1 mins
Clinical trial
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active or chronic active antibody mediated rejection (AMR) after recently been kidney transplanted.

1 min
Clinical trial
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1).

1 min

Journal
Neoplastic disease after liver transplantation: Focus on de novo neoplasms

De novo neoplasms account for almost 30% of deaths 10 years after liver transplantation and are the most common cause of mortality in patients surviving at least 1 year after transplant.

1 mins
Journal
Combined and sequential liver-kidney transplantation in children

Combined and sequential liver-kidney transplantation (CLKT and SLKT) is a definitive treatment in children with end-stage organ failure. There are two major indications: - terminal insufficiency of both organs, or - need for transplanting new liver as a source of lacking enzyme or specific regulator of the immune system in a patient with renal failure.

1 min
Journal
OPTN/SRTR 2017 Annual Data Report: Liver

Data on adult liver transplants performed in the US in 2017 are notable for (1) continued growth in numbers of new waitlist registrants (11,514) and of transplants performed (8,082); (2) continued increase in the transplant rate (51.5 per 100 waitlist-years)...

1 min

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).